SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Glüer CC, Krueger K, Cohen FJ, Eckerd S, Ensrud KE, Avioli LV, Lips P, Cummings SR 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial. JAMA 282:637645.
  • 2
    Grey AB, Stapleton JP, Evans MC, Tatnell MA, Reid IR 1996 Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism. Ann Intern Med 125:360368.
  • 3
    McKane WR, Khosla S, Burritt MF, Kao PC, Wilson DM, Ory SJ, Riggs BL 1995 Mechanism of renal calcium conservation with estrogen replacement therapy in women in early postmenopause—a clinical research center study. J Clin Endocrinol Metab 80:34583464.
  • 4
    Nordin BE, Need AG, Morris HA, Horowitz M, Robertson WG 1991 Evidence for a renal calcium leak in postmenopausal women. J Clin Endocrinol Metab 72:401407.
  • 5
    Diamond T, Ng AT, Levy S, Magarey C, Smart R 1996 Estrogen replacement may be an alternative to parathyroid surgery for treatment of osteoporosis in elderly postmenopausal women presenting with primary hyperparathyroidism: A preliminary report. Osteoporos Int 6:329333.
  • 6
    Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C 1996 A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res 11:835842.
  • 7
    Heaney RP, Draper MW 1997 Raloxifene and estrogen: Comparative bone-remodeling kinetics. J Clin Endocrinol Metab 82:34253429.